Neurodegenerative Diseases News and Research

RSS

European researchers develop new form of therapy for Alpha-mannosidosis

Alpha-mannosidosis is a rare childhood disease which causes symptoms such as mental retardation or hearing loss and is linked to a lower life expectancy. A European research team headed by Professor Paul Saftig from Christian-Albrechts-Universit-t zu Kiel has developed a form of therapy as part of the Alpha-Man project, which will receive around six million euros from the European Union for its next stage of trials.

9 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

The discovery by UCLA biochemists of a new method for preventing oxidation in the essential fatty acids of cell membranes could lead to a new class of more effective nutritional supplements and potentially help combat neurodegenerative disorders such as Parkinson's disease and perhaps Alzheimer's.

3 Dec 2010

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson's disease, a debilitating neurological condition with considerable unmet need for new treatments.

1 Dec 2010

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Nov 2010

Molecular switch plays crucial role in addictive behavior and memory processes

Learning and memory formation are based on the creation of new connections between neurons in the brain. Also, behaviors such as nicotine addiction manifest themselves in long-term changes of neuronal connectivity and can - at least in this respect - be viewed as a form of learning.

30 Nov 2010

Diabetes drug may counteract against Alzheimer's disease: Research

Metformin, a drug used in type 2-diabetes might have the potential to also act against Alzheimer's disease. This has been shown in a study from scientists of the German Center for Neurodegenerative Diseases (DZNE), the University of Dundee and the Max-Planck-Institute for Molecular Genetics.

24 Nov 2010

Rate, direction of axon growth in spinal cord can be controlled, study shows

Both the rate and direction of axon growth in the spinal cord can be controlled, according to new research by USC College's Samantha Butler and her collaborators.

23 Nov 2010

New editorial dispel doubts about Lou Gehrig's ALS diagnosis

A recent study suggesting that amyotrophic lateral sclerosis (ALS) may be attributed to repetitive head trauma experienced in collision sports lacks scientific epidemiological evidence to support this claim.

20 Nov 2010

Pericyte cells become key players in shaping blood flow in the brain

Cells in the brain called pericytes that have not been high on the list of targets for treating diseases like Alzheimer's may play a more crucial role in the development of neurodegenerative diseases than has been realized.

18 Nov 2010

Imec and PEIRA develop platform for in-vitro study of brain tissue

The nanoelectronics research centre imec and Peira, a Belgium-based manufacturer of pharmaceutical and chemical research instruments, jointly developed an innovative slice-tilting instrument for in-vitro research on brain tissue. The new tool enables long-term studying of brain cultures through electronic stimulation and read-out, essential in getting insight into the functioning of the brain.

17 Nov 2010

New slice-tilting instrument for in-vitro research on brain tissue

17 Nov 2010

Researchers improvise fruit fly as a model system to study brain development, disorders

VIB researchers attached to the K.U.Leuven have improved the fruit fly as a model for studying the connections between brain cells. The researchers developed a specific marker for a part of the fly's nerve cell which had previously been difficult to distinguish. Their discovery will not only contribute to gaining a better insight into brain development but also makes the fruit fly into a better model system for studying brain development and brain disorders.

15 Nov 2010

Cortex third quarter net loss decreases to $528,000

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $528,000, or $0.01 per share, for the quarter ended September 30, 2010, compared with a net loss applicable to common stock of approximately $3,243,000 or $0.06 per share, for the prior year quarter.

12 Nov 2010

Researchers study Rett neurons in a Petri dish

A collaborative effort between researchers at the Salk Institute for Biological Studies and the University of California, San Diego, successfully used human induced pluripotent stem (iPS) cells derived from patients with Rett syndrome to replicate autism in the lab and study the molecular pathogenesis of the disease.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

High cholesterol in midlife does not increase risk for Alzheimer's disease among women

High cholesterol levels in middle age do not appear to increase women's risk of developing Alzheimer's disease and other forms of dementia later in life, new Johns Hopkins-led research finds, despite a body of scientific evidence long suggesting a link between the two.

11 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

Neurodegenerative Diseases News and Research

European researchers develop new form of therapy for Alpha-mannosidosis

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Molecular switch plays crucial role in addictive behavior and memory processes

Diabetes drug may counteract against Alzheimer's disease: Research

Rate, direction of axon growth in spinal cord can be controlled, study shows

New editorial dispel doubts about Lou Gehrig's ALS diagnosis

Pericyte cells become key players in shaping blood flow in the brain

Imec and PEIRA develop platform for in-vitro study of brain tissue

New slice-tilting instrument for in-vitro research on brain tissue

Researchers improvise fruit fly as a model system to study brain development, disorders

Cortex third quarter net loss decreases to $528,000

Researchers study Rett neurons in a Petri dish

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

High cholesterol in midlife does not increase risk for Alzheimer's disease among women

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News